<DOC>
	<DOCNO>NCT02965092</DOCNO>
	<brief_summary>Chimeric antigen receptor ( CAR ) consist single chain variable fragment ( scFv ) activation domain T cell , CAR-modified T cell ( CAR-T cell ) capability recognize tumor associate antigen kill tumor cell specifically . To large part patient refractory relapse B cell malignancy , CAR-T cell adoptive immunotherapy play revolutionary effect field cancer treatment . The investigator believe cell CD137 good chance kill leukemia cell . In lab , investigator construct second generation CAR contain CD137 . The investigator start Phase I study aim relapsed refractory B cell malignancy . The purpose study evaluate safety effectiveness CD19 CAR-T cell patient .</brief_summary>
	<brief_title>CD19 Chimeric Antigen Receptor ( CAR ) -Modified T Cell Therapy Treating Patients With Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>CD19 CAR-T strong effect anti-tumor capacity . While people able control clinical complication , conduct CD19 CAR-T clinical trial strong demand value . The investigator construct second generation CAR contain CD137 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>1 . Pathologically histologically confirm CD19 + B cell tumor , patient currently effective treatment option , chemotherapy autologous hematopoietic stem cell transplantation ( autoHSCT ) / relapse allogeneic hematopoietic stem cell transplantation ( alloHSCT ) treatment ; patient voluntarily choose CD19 CART cell first treatment ; 2 . B cell hematological malignancy include follow three category : 1 ) Bcell acute lymphocytic leukemia ( BALL ) ; 2 ) Indolent Bcell lymphoma ( CLL , FL , MZL , LPL ) ; 3 ) Aggressive Bcell lymphoma ( DLBCL , BL , MCL ) ; 3 . &lt; 60 year old ; 4 . Expected survival time &gt; 6 month ; 5 . Female patient around childbearing age , negative pregnancy test trial , agree take effective contraceptive measure trial last visit ; 6 . Voluntarily participate experiment sign inform consent themself , legally authorize representative . 1 . With history epilepsy central nervous system diseases ; 2 . Having graftversushost reaction , require use immunosuppressant ; 3 . The presence clinically significant cardiovascular disease , uncontrolled symptomatic arrhythmia , congestive heart failure myocardial infarction within recent six month , heart disease cardiac function grade 3 ( moderate ) 4 ( severe ) ( accord New York Heart Association ( NYHA ) Functional Classification System ) ; 4 . Pregnant lactate woman ( safety therapy unborn child unknown ) ; 5 . Not curable active infection ; 6 . Patients active hepatitis B hepatitis C virus infection ; 7 . Combined use systemic steroid within two week ( except use inhale steroid recently currently ) ; 8 . Using product gene therapy ; 9 . Creatinine &gt; 2.5 mg / dl ( 221.0 umol/L ) ; ALT / AST &gt; 3 X normal amount ; Bilirubin &gt; 2.0 mg / dl ( 34.2 umol/L ) ; 10 . Patients suffer uncontrolled disease , researcher believe patient suitable trial ; 11 . Patients HIVinfection ; 12 . Researchers believe situation may increase risk patient interfere test result .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>